Lowey Dannenberg, P.C. is Investigating Nutex Health, Inc. (Nasdaq: NUTX) for Potential Violations of the Federal Securities Laws and Encourages Investors with more than $50,000 in Losses to Contact the Firm
NEW YORK, March 10, 2026 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, is investigating Nutex Health, Inc. (“Nutex” or the “Company”) (Nasdaq: NUTX) for potential violations of the federal securities laws.
Shares of Nutex Health fell more than 24% in pre-market trading on March 6, 2026, after the company reported its fourth quarter and full-year 2025 results. Nutex disclosed that many out-of-network reimbursement claims it submitted through the federal Independent Dispute Resolution process were ultimately deemed ineligible. The Company said its results included “a one-time $55.0 million cumulative true-up of 18,950 arbitration claims that arbitrators determined were ineligible under the IDR process.”
If you suffered a loss of more than $50,000 in Nutex securities, and wish to participate, learn more, or discuss the issues surrounding the investigation, please contact attorneys at (914) 733-7256 or via email to Andrea Farah (afarah@lowey.com) or Vincent R. Cappucci Jr. (vcappucci@lowey.com).
About Lowey Dannenberg
Lowey Dannenberg is a national firm representing institutional and individual investors, who suffered financial losses resulting from corporate fraud and malfeasance in violation of federal securities and antitrust laws. The firm has significant experience in prosecuting multi-million-dollar lawsuits and has previously recovered billions of dollars on behalf of investors.
Contact
Lowey Dannenberg P.C.
44 South Broadway, Suite 1100
White Plains, NY 10601
Tel: (914) 733-7256
Email: investigations@lowey.com
SOURCE: Lowey Dannenberg
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
